A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Metformin, an OCT2 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Oral Dose of Vandetanib (CAPRELSA) 800 mg.

Trial Profile

A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Metformin, an OCT2 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Oral Dose of Vandetanib (CAPRELSA) 800 mg.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Metformin; Vandetanib
  • Indications Cancer; Diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 22 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top